Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases
New extension of Synflorix vaccine supply agreement will help protect an additional 80 million children in the world’s poorest countries from pneumococcal disease.
Read more -
GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection
GSK announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Revolade™ (e...
Read more -
Results announcement for the second quarter 2013
GSK announces Q2 core EPS growth of 4% and dividend of 18p
Read more -
GSK statement regarding recent meeting with Chinese authorities
Following a meeting with the Chinese Ministry of Public Security to discuss their investigation into GSK, Abbas Hussain, President International - Europe, Japan, Emerging Market...
Read more -
Update on GSK Consumer Nigeria plc Scheme of Arrangement
GlaxoSmithKline plc and GlaxoSmithKline Consumer Nigeria PLC today announced that they have agreed that the scheme of arrangement proposed to GSK Nigeria's shareholders in the s...
Read more -
GSK response to China investigation
In response to the ongoing investigations by government authorities in China regarding our business in the country, GSK has issued the following statement.
Read more -
Regulatory update: fluticasone furoate/vilanterol submission in Japan
GSK and Theravance, Inc. announce that the licence application for the use of fluticasone furoate (FF) and vilanterol (VI) (proposed brand name RELVAR™ ELLIPTA™) in patients wit...
Read more -
Regulatory update – GSK announces US submission for dabrafenib/trametinib combination in metastatic melanoma
GSK today announced submission of supplemental New Drug Applications (NDAs) to the US Food and Drug Administration for use of dabrafenib, a BRAF inhibitor, in combination with t...
Read more -
Regulatory Update - GSK receives positive CHMP opinions for Tafinlar® (dabrafenib) and Tyverb® (lapatinib)
GSK announces that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is recommending marketing authorisation for two cancer drugs.
Read more -
GSK and Save the Children launch $1 million award to discover new healthcare innovations for reducing child deaths
The Healthcare Innovation Award is the first joint initiative announced following the launch of an ambitious new partnership between GSK and Save the Children
Read more -
GlaxoSmithKline’s drisapersen (previously GSK2402968/PRO051) to receive Food and Drug Administration Breakthrough Therapy designation
Breakthrough Therapy designation is one of several programmes created by the FDA to expedite the development and review of drugs for serious or life-threatening conditions.
Read more -
GSK announces data from five Phase III studies of albiglutide, an investigational once-weekly treatment for type 2 diabetes
Data from five long-term Phase III studies comparing albiglutide to placebo and a range of active comparators were presented at the American Diabetes Association Meeting (ADA) i...
Read more -
GSK receives offer for its thrombosis brands and related manufacturing site
GSK has today received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB) site from Aspen Global Incorporated and Aspen Pharmacare Holdings Limited.
Read more -
GSK statement regarding 2010 Nature Medicine study
GSK and Nature Medicine recently became aware of allegations of misrepresentation of data in a research paper written by scientists at GSK's China research centre and published ...
Read more -
GSK statement in response to FDA Advisory Committee’s vote on availability of Avandia (rosiglitazone)
GSK confirmed today that a joint advisory committee to the FDA voted to continue to make Avandia (rosiglitazone) available to appropriate patients with the majority of the membe...
Read more -
GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric cancer
GSK today announced that its study of TYKERB/TYVERB® (lapatinib) in combination with chemotherapy in patients with HER2-positive advanced gastric cancer did not meet the primary...
Read more -
GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian cancer
GSK today announced that its Phase III clinical trial of VOTRIENT (pazopanib) met the primary objective of a statistically significant improvement in the time to disease progres...
Read more -
GSK strengthens vaccines business with acquisition of Okairos
GSK today announced that it has acquired Okairos AG (Okairos), a specialist developer of vaccine platform technologies for €250 million (approximately £215 million/$325 million)...
Read more -
GSK and Genmab announce positive top-line results from pivotal trial of ARZERRA® (ofatumumab) combined with chlorambucil in previously untreated chronic lymphocytic leukaemia
GSK and Genmab announce that their Phase III study of ARZERRA® (ofatumumab) in combination with chlorambucil versus chlorambucil alone in patients with previously untreated chro...
Read more -
Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies
GSK announced today that the FDA has approved both TAFINLAR® (dabrafenib) and MEKINIST™ (trametinib).
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
